From the room, not the press release.

Six peptides cleared an FDA panel. None of them are legal to compound today.

The agency's advisory committee recommended six of seven peptides for the 503A bulks list. The headlines called it approval. It isn't — and the last substance to clear this committee on the same margin is still waiting, four years on.